Tucson, Arizona 85724

  • Sarcoma


RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with advanced soft tissue sarcomas.

Study summary:

OBJECTIVES: - Determine the objective response rate (confirmed, complete, and partial) in patients with advanced soft tissue sarcomas treated with sorafenib. - Determine the 4-month progression-free survival rate in patients treated with this drug. - Determine the frequency and severity of adverse events in patients treated with this drug. OTHER OBJECTIVES (if funding permits): - Correlate, preliminarily, a decrease in standard uptake variable (SUV) of target lesions by positron-emission tomography scan at 4 weeks with response in patients treated with this drug. - Correlate, preliminarily, the phosphorylation status of KIT, PDGFR, VEGFR, and the raf/mek/erk pathway with response in patients treated with this drug. - Correlate, preliminarily, the most common B-raf kinase mutation with response in patients treated with this drug. OUTLINE: This is a multicenter study. Patients are stratified according to histology (leiomyosarcoma vs liposarcoma vs angiosarcoma, hemangiosarcoma, or hemangiopericytoma). Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 8 weeks until disease progression and then every 6 months for 2 years and annually for up to 3 years. PROJECTED ACCRUAL: A total of 45-75 patients (15-25 per stratum) will be accrued for this study within 15-38 months.


DISEASE CHARACTERISTICS: - Histologically confirmed soft tissue sarcoma of 1 of the following histologies: - Angiosarcoma, cutaneous or visceral - Malignant hemangiosarcoma - Malignant hemangiopericytoma - Grade 3-4 leiomyosarcoma - Grade 3-4 liposarcoma - Must have evidence of unresectable residual disease, metastatic disease, or recurrent disease by radiography - Measurable disease by x-ray, scans, or physical examination - Archived paraffin-embedded tumor sections available - No known brain metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Zubrod 0-1 Life expectancy - Not specified Hematopoietic - WBC ≥ 3,000/mm^3 - Absolute neutrophil count ≥ 1,500/mm^3 - Platelet count ≥ 100,000/mm^3 Hepatic - SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if due to liver metastases) - Bilirubin normal (≤ 2.5 times ULN if due to liver metastases) - PT, PTT, and INR normal Renal - Creatinine normal OR - Creatinine clearance ≥ 60 mL/min Cardiovascular - No history of thromboembolic disease - No uncontrolled hypertension Other - Not pregnant or nursing - Fertile patients must use effective contraception - Able to swallow oral medication - No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - At least 28 days since prior chemotherapy (42 days for carmustine or mitomycin) and recovered - Prior adjuvant chemotherapy allowed - No more than 1 prior chemotherapy regimen for metastatic disease Endocrine therapy - Not specified Radiotherapy - At least 28 days since prior radiotherapy and recovered - Must have evidence of disease progression within, or measurable disease outside of, the radiation field after completion of radiotherapy Surgery - At least 28 days since prior major surgery and recovered Other - No prior sorafenib - No prior inhibitor of VEGFR or MAPK pathway - No concurrent combination antiretroviral therapy for HIV-positive patients - No other concurrent investigational agents - No concurrent therapeutic anticoagulation - No concurrent administration of any of the following medications: - Rifampin - Hypericum perforatum (St. John's wort) - Cytochrome P450 enzyme-inducing antiepileptic drugs, including any of the following: - Phenytoin - Carbamazepine - Phenobarbital

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas

Official Title:

Phase II Trial of BAY-9006 (NSC #724772) in Advanced Soft Tissue Sarcomas

Overall Status:


Study Phase:

Phase 2



Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Southwest Oncology Group

Oversight Authority:

  • United States: Federal Government
  • United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Intervention Model: Single Group Assignment, Mask

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Margaret von Mehren, MD
Study Chair
Fox Chase Cancer Center

Study Dates

Start Date:March 2006
Completion Date:September 2012
Completion Type:Actual
Primary Completion Date:April 2008
Primary Completion Type:Actual
Verification Date:November 2012
Last Changed Date:November 2, 2012
First Received Date:September 20, 2005
First Results Date:October 3, 2012

Study Outcomes

Outcome Type:Primary Outcome
Measure:Objective Response (Confirmed, Complete and Partial)
Time Frame:Assessment performed every eight weeks until progression.
Safety Issues:False
Description:Partial response (PR) is greater than or equal to 30% decrease under baseline of sum of longest diameters of all target measurable lesions; No unequivocal progression of non-measurable disease; No new lesions. Unconfirmed PR is one objective status of PR
Outcome Type:Secondary Outcome
Measure:Four-month Progression-free Survival Rate
Time Frame:0 - 4 months
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
Time Frame:Patients were assessed for adverse events two weeks after starting protocol treatment and then after
Safety Issues:True
Description:Adverse Events (AEs) are reported by the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0. For each patient, worst grade of each event type is reported. Grade 3 - Severe, Grade 4 - Life-threatening, Grade 5 - Fatal. Only adverse even

Study Interventions

Intervention Type:Drug
Description:800 mg per day, daily until progression
Arm Name:sorafenib
Other Name:BAY 43-9006

Study Arms

Study Arm Type:Experimental
Arm Name:sorafenib

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Southwest Oncology Group
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Results Reference
Citation:Ryan CW, von Mehren M, Rankin CJ, et al.: Phase II intergroup study of sorafenib (S) in advanced soft tissue arcomas (STS): SWOG 0505. [Abstract] J Clin Oncol 26 (Suppl 15): A-10532, 2008.

Data Source: ClinicalTrials.gov

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.